Performance evaluation of a pediatric viscous impeller pump for Fontan cavopulmonary assist

Guruprasad A. Giridharan, PhD,a Steven C. Koenig, PhD,a Jeffrey Kennington, BS,b Michael A. Sobieski, RN, CCP,a Jun Chen, PhD,b Steven H. Frankel, PhD,b and Mark D. Rodefeld, MDc

Objective: The anatomic and physiologic constraints for pediatric cavopulmonary assist differ markedly from adult Fontan circulations owing to smaller vessel sizes and risk of elevated pulmonary resistance. In this study, hemodynamic and hemolysis performance of a catheter-based viscous impeller pump (VIP) to power the Fontan circulation is assessed at a pediatric scale (~15 kg) and performance range (0-30 mm Hg).

Methods: Computer simulation and mock circulation studies were conducted to assess the hydraulic performance, acute hemodynamic response to different levels VIP support, and the potential for vena caval collapse. Computational fluid dynamics simulations were used to estimate VIP hydraulic performance, shear rates, and potential for hemolysis. Hemolysis was quantified in a mock loop with fresh bovine blood.

Results: A VIP augmented 4-way total cavopulmonary connection flow at pediatric scales and restored systemic pressures and flows to biventricular values, without causing flow obstruction or suction. VIP generated flows up to 4.1 L/min and pressure heads of up to 38 mm Hg at 11,000 rpm. Maximal shear rate was 160 Pa, predicting low hemolysis risk. Observed hemolysis was low with plasma free hemoglobin of 11.4 mg · dL⁻¹ · h⁻¹.

Conclusions: A VIP will augment Fontan cavopulmonary flow in the proper pressure and flow ranges, with low hemolysis risk under more stringent pediatric scale and physiology compared with adult scale. This technology may be developed to simultaneously reduce systemic venous pressure and improve cardiac output after stage 2 or 3 Fontan repair. It may serve to compress surgical staging, lessening the pathophysiologic burden of repair.

(J Thorac Cardiovasc Surg 2013;145:249-57)

Despite advances, palliative repair of functional single ventricle remains an enigmatic challenge. Intractable morbidities in the interim-staged palliative approach include severe hypoxemia, ventricular hypertrophy, sudden hemodynamic instability, and neurocognitive dysfunction. Late sequelae have been linked to prior repair in which a shunt source of pulmonary blood flow and resolve the associated hallmarks of hypoxemia, ventricular volume overload, unstable parallel circulations, and impaired diastolic coronary perfusion. A clinical device to accomplish this does not currently exist.

To address these problems, we are developing an expandable viscous impeller pump (VIP) to provide temporary cavopulmonary support. The VIP is a catheter-based, biconical, vaned rotary pump that can be inserted percutaneously using a modified Seldinger technique and advanced to the cavopulmonary junction via either the superior or inferior vena cava and expanded (Figure 1). The biconical design of the VIP allows for simultaneous pumping of blood from both the superior and inferior vena cavae to each of the pulmonary arteries using only a single pump head. The VIP is designed to fit within the cavopulmonary junction of a pediatric patient and is stabilized inside the cavopulmonary junction by an expandable nitinol cage.

In pediatric patients, the anatomic and physiologic constraints for cavopulmonary assist are more stringent than for adults with failing Fontan circulations. Chief among these are smaller vessel size and risk of elevated pulmonary vascular resistance. This study was performed to assess...
Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASTM</td>
<td>American Society of Testing and Materials</td>
</tr>
<tr>
<td>CFD</td>
<td>computational fluid dynamics</td>
</tr>
<tr>
<td>H-Q</td>
<td>pump hydraulic performance</td>
</tr>
<tr>
<td>TCPC</td>
<td>total cavopulmonary connection</td>
</tr>
<tr>
<td>VIP</td>
<td>viscous impeller pump</td>
</tr>
</tbody>
</table>

**METHODS**

**Computer Simulation Study**

A previously reported computer simulation model of the pediatric biventricular cardiovascular system was modified to simulate single-ventricle Fontan physiology of a 4-year-old (~15 kg) child. The biventricular computer simulation model has been used in previous studies to develop and test physiologic control algorithms for mechanical circulatory support devices. In brief, the computer model subdivides the Fontan circulatory system into 2 heart valves and 8 blocks, which include common atrium, single ventricle, pulmonary and systemic circulations, vena cava, aorta, and coronary circulation. The volume of blood in each block is described by a differential equation as a function of volume (V), pressure (P), compliance (C), and resistance (R), which is an expression for the macroscopic material balance for the block given by:

$$\frac{dV_n}{dt} = F_n - F_{in} - \frac{dV_n}{dt} = \frac{V_{n+1} - V_n}{C_nR_n} + \frac{V_n}{C_nR_n} + \frac{1}{C_{n+1}}$$

where $dV_n$ is the rate of change of volume in block n, $F_n$ is the blood flow rate into the block, and $F_{in}$ is the blood flow rate out of the block. The heart rate, resistances, and compliances were modified to reproduce hemodynamic pressure and flow waveforms of the univentricular Fontan physiology of a 4-year-old child based on literature and clinical guidance. A model of the VIP was integrated at the cavopulmonary junction. Simulations were conducted to predict acute hemodynamic responses from 0 to 3.5 L/min of VIP support in 0.25-L/min increments. Ventricular, aortic, and ventricular pressures, aortic, coronary, and caval pulmonary flows, and ventricular volume and external work were calculated. These parameters were compared with normal biventricular physiologic values.

**Mock Circulation Studies**

**Acute hemodynamic performance.** A mock circulation system consisting of a silicone ventricle, aorta, systemic and pulmonary resistances and compliances, and a cavopulmonary junction was used to simulate the univentricular Fontan circulation. The cavopulmonary junction is rigid with 11-mm diameter superior and inferior vena cavae and 9-mm diameter pulmonary arteries that are connected to flexible silicone tubing. The prototype pediatric VIP measures 9.75 mm in height and 9.5 mm in diameter (expanded). Ventricular pressure, heart rate, systemic and pulmonary resistances, and compliances were adjusted to reproduce hemodynamic waveforms of univentricular Fontan physiology of a 4-year-old child. Baseline hemodynamic pressure and flow data were collected for the univentricular Fontan circulation (no VIP support). The VIP was introduced at the cavopulmonary junction and data were collected at VIP rotational speeds of 3000 to 11,000 rpm. The venae cavae were partially clamped (60%) to test for risk of vena caval collapse (negative vena caval pressure) with the VIP operating at its maximum operational speed of 11,000 rpm. The potential of the VIP to impede Fontan cavopulmonary flow during pump failure was studied by stopping VIP rotation while leaving the fully deployed device in place in the midst of the cavopulmonary junction. The hemodynamic effect of off-center alignment of the VIP along the axis of the venae cavae in the cavopulmonary junction was studied by placing the VIP at 20%, 40%, 60%, 80%, and 100% offset conditions along the axis of the inferior vena cava. A 20% offset implies that the VIP was placed 20% of the radius of the pulmonary artery away from the optimal location in the total cavopulmonary connection (TCPC) along the axis of the inferior vena cava.

**Hydraulic performance.** A mock circulation consisting of a cavopulmonary junction with VIP and a resistor was used to characterize hydraulic performance of the VIP. The VIP was operated at 3000 to 11,000 rpm and against 5 different resistances at each pump speed. Steady state pressure head and flow rates generated by the VIP were recorded for each operational condition and plotted (H-Q curve) to characterize hydraulic performance.

**Data collection and analysis.** Hemodynamic data were collected using a clinically approved good laboratory practices (GLP)-compliant data acquisition system. All transducers were precalibrated and postcalibrated against known standards to ensure measurement accuracy. In hemodynamic studies, pressure and flow waveforms were used to calculate heart rate, stroke volume, cardiac output, mean aortic pressure, cavopulmonary pressures, left atrial pressure, and aortic and cavopulmonary flows on a beat-to-beat basis by using the HEART program developed in Matlab (MathWorks, Natick, Mass) and averaged to obtain a single mean value. In hydraulic performance characterization studies, pressure and flow waveforms were used to calculate average pressure head across the VIP and average flow rates.

**CFD Study**

Fresh whole bovine blood (~48 hours) was used in an in vitro blood loop to quantify VIP hemolysis (Figure 2, B). Blood was heparinized to an activated clotting time greater than 300 seconds, and hematocrit value was adjusted to 28% ± 2% with plasma buffer solution. VIP was operated at 9000 rpm against a pressure head of 15 ± 2 mm Hg resulting in a flow rate of 2.2 ± 0.3 L/min. Total blood volume in the in vitro loop was 1 L. In vitro blood damage was assessed by measuring plasma free hemoglobin, hematocrit, red blood cell, white blood cell, and platelet counts before device operation (baseline) and every hour thereafter for 6 hours. The plasma free hemoglobin was quantified using a Plasma Photometer (HemoCue, Mission Viejo, Calif). Platelet count and hematocrit were measured using CDC Mascot (CDC Technologies, Oxford, Conn). Normalized index of hemolysis was calculated using American Society of Testing and Materials (ASTM) standards. The hemolysis study parameters and protocols comply with Food and Drug Administration guidelines for 510(k) submission and ASTM standards.
RESULTS

Computer Simulation

The unsupported Fontan circulation results in diminished cardiac output and aortic systolic and diastolic pressures compared with normal biventricular circulation (Table 1). VIP support increases cardiac output, ventricular end-diastolic pressures and volumes, and aortic systolic and diastolic pressures in patients with Fontan circulations (Figure 3). One hundred–percent VIP support restored cardiac output, ventricular end-diastolic pressures, and aortic systolic and diastolic pressures to normal biventricular circulation values. VIP support increased the ventricular end-systolic and end-diastolic volumes from baseline Fontan values (Figure 3, C). Significantly, the restoration of hemodynamic parameters of the Fontan circulation to near normal values was achieved with only a modest shift of pressure head (~6 mm Hg) in the cavopulmonary junction (CPPH = pressure difference between the venae cavae and proximal pulmonary arteries, Table 1, Figure 3). A simulated VIP flow of 3.5 L/min is higher than the predicted cardiac output of 3.3 L/min owing to 0.2-L/min of retrograde flow (recirculation) around the VIP.

Mock Circulation

Mock circulatory system experiments demonstrate that VIP support augments cardiac output by up to 23% and mean common atrial pressure by up to 22 mm Hg at its maximal operational speeds. Further, VIP support increases pulmonary arterial pressure, aortic systolic and diastolic pressures, and ventricular end-systolic and end-diastolic volumes. Importantly, only a modest (8 mm Hg) shift of cavopulmonary pressure head in the direction of the single ventricle leads to these significant improvements in hemodynamic parameters of the Fontan circulation. The percentage increase in cardiac output and cavopulmonary pressure head are consistent with computer simulation results (Table 2 and Figure 3, B).

No cavitation was observed at 11,000 rpm, the maximum rotational speed for the VIP. Partial clamping (50%-60%) of the venae cavae with the VIP at 11,000 rpm reduced
mean vena caval pressure from 8 to 5 mm Hg. Substantial clamping (over 80%) of the venae cavae was necessary to generate negative vena caval pressure (indicative of vena caval collapse with the VIP operating at 11,000 rpm.

Simulated VIP failure (nonrotation) reduced cardiac output to baseline Fontan values. Improper alignment of the VIP at the cavopulmonary junction by up to 80% of the radius of the pulmonary arteries did not significantly affect the overall flow rate. However, substantial reduction (>20%) in flow was observed when the VIP impeller was placed at an offset that exceeded 80% of the radius of the pulmonary arteries.

Hydraulic characterization demonstrates that the VIP is capable of pumping up to 4.1 L/min and can pump against a pressure head of up to 38 mm Hg (Figure 4, A). The H-Q curves show a substantially flat performance profile, ideal for mechanical circulatory support devices.

CFD

CFD did not predict any areas of low velocity or low shear stress, suggesting minimal risk of blood stagnation in the VIP. Peak velocities of 7 m/s were observed at the vane edges, but CFD predicted low hemolysis rates with a maximal shear stress of 160 Pa at 11,000 rpm (clinical threshold \( z \approx 400 \text{ Pa}^{17} \); Figure 4, B). A vena caval offset of 20% did not diminish average flow rates compared with the no vena caval offset condition.

Hemolysis Testing

The plasma free hemoglobin at the beginning of the 6-hour test period was 0 mg/dL. At the end of the 6-hour test period it was 70 mg/dL (average hemolysis rate \( = 11.4 \text{ mg} \cdot \text{dL}^{-1} \cdot \text{h}^{-1} \); peak hemolysis rate \( = 20 \text{ mg} \cdot \text{dL}^{-1} \cdot \text{h}^{-1} \)). The Normalized Index of Hemolysis, calculated per ASTM standards, was 0.07 g/100 L. Hematocrit, red and white blood cell counts, and platelet counts over the 6-hour period did not vary significantly from baseline.

DISCUSSION

Mechanical cavopulmonary assist within the TCPC presents unique anatomic and physiologic challenges that are markedly dissimilar from any other mechanical circulatory support application. Flow must be augmented in a highly complex 3- or 4-axis geometry in which incoming and outgoing flows are perpendicular. The pump will provide support in a location where no ventricle will recover to assume

TABLE 1. Simulation of cavopulmonary assist device flow for normal, Fontan circulation without, and Fontan circulation with VIP support

<table>
<thead>
<tr>
<th>Case</th>
<th>HR (beats/min)</th>
<th>SV (mL)</th>
<th>CO (L/min)</th>
<th>CO % increase</th>
<th>AoP (mm Hg)</th>
<th>CPPH (mm Hg)</th>
<th>VIP flow (L/min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>120</td>
<td>26.2</td>
<td>3.26</td>
<td>—</td>
<td>87.7/54.2</td>
<td>—</td>
<td>0</td>
</tr>
<tr>
<td>Fontan</td>
<td>110</td>
<td>26.0</td>
<td>2.83</td>
<td>—</td>
<td>80.3/51.0</td>
<td>0.3</td>
<td>0</td>
</tr>
<tr>
<td>Fontan + partial VIP</td>
<td>110</td>
<td>26.9</td>
<td>2.96</td>
<td>4.6</td>
<td>80.6/51.1</td>
<td>0.1</td>
<td>1.75</td>
</tr>
<tr>
<td>Fontan + partial VIP</td>
<td>110</td>
<td>26.9</td>
<td>3.30</td>
<td>16.6</td>
<td>87.1/53.0</td>
<td>5.5</td>
<td>3.5</td>
</tr>
</tbody>
</table>

Viscous impeller pump (VIP) support increases the Fontan circulation cavopulmonary pressure head, cardiac output, and aortic pressures to near normal biventricular values. A simulated VIP flow of 3.5 L/min (full support) is higher than the predicted cardiac output of 3.3 L/min owing to retrograde flow (recirculation, \( \approx 0.2 \text{ L/min} \)) around the VIP. VIP, Viscous impeller pump; HR, heart rate; SV, stroke volume; CO, cardiac output; CO % increase, percent increase from baseline Fontan cardiac output; AoP, aortic pressure; CPPH, cavopulmonary pressure head = vena cava pressure – pulmonary artery pressure.
function of the pump; thus, it is not a ventricular assist device. The ambient cavopulmonary pressures are low (10-15 mm Hg) and the ideal pump should generate a substantial amount of flow while maintaining a low pressure head (6-8 mm Hg) to avoid perfusion injury to the lung. However, higher pressure heads (~20-30 mm Hg) may be required in pediatric patients with Fontan circulations who have precapillary pulmonary hypertension that is unresponsive to pharmacologic therapy. Because there is no volume reservoir for the pump inlet to draw from, vein collapse and cavitation owing to inlet suction must be avoided. Additionally, there is no natural barrier (such as a valve) present within the TCPC pathway to prevent recirculation around the pump body. Significant recirculation around the pump would reduce hydraulic efficiency and may increase the risk of hemolysis. Finally, it is critical that the
cavopulmonary pathways remain unobstructed during pump deployment, weaning, pump shutoff or failure, and after the pump is withdrawn.

Implantation of microaxial pumps in the superior and/or inferior venae cavae has been proposed as a means of providing cavopulmonary support. Implantation of one microaxial pump in the superior or inferior vena cava alone would lead to undesirable back pressure in the opposing vena cava. Implantation of two microaxial pumps in the superior and inferior venae cavae have significant limitations, including: (1) need to implant two devices to satisfactorily augment the double-inlet/double-outlet flow.

FIGURE 3. (continued).

ET/BS
A pattern characteristic of the TCPC, increasing the complexity of implantation and explantation, and risk of failure; (2) obstructive to flow, which significantly limits the ability to wean support to no net contribution to Fontan flow and may be catastrophic in the event of pump failure; (3) have an inherently high risk of inlet suction owing to high rotational speed; (4) any imbalance in flows between the pumps will lead to undesirable back pressure; and (5) have a high degree of complexity and very low manufacturing tolerances, which may increase risk of mechanical failure. To avoid these limitations, Lacour-Gayet and associates have proposed modification of the existing Fontan junction to a Y-shaped 3-way junction. Although this approach enables Fontan support using a single microaxial pump, it would require an additional major surgical procedure with cardiopulmonary bypass to reconstruct the Fontan cavopulmonary junction. Further, implantation of a microaxial pump in a 3-way junction (with or without a barrier to recirculation) would have obstructive potential, which will complicate the ability to wean cavopulmonary support and may be catastrophic in the case of pump failure.

To overcome these limitations, we are developing a cavopulmonary assist device (VIP) that is both expandable and multidirectional, and can be implanted percutaneously. The biconical design of the VIP allows for a single impeller to stabilize and augment cavopulmonary flow in 4 axes. No reconstruction of the existing cavopulmonary junction is required. Computer simulation and mock circulation results demonstrate that the VIP may augment cavopulmonary flow and restore cardiac output, ventricular pressures and volumes, and aortic pressures to normal biventricular values with only a modest rise in cavopulmonary pressure head (6-8 mm Hg). Importantly, these hemodynamic benefits were observed with the VIP operating at nominal operational speeds (5000-7000 rpm, Table 2). Operation of the VIP at higher rotational speeds (9000-11,000 rpm) in pediatric Fontan patients with normal pulmonary resistance may lead to significant increases in pulmonary artery and atrial pressures (Table 2) without a significant increase in cardiac output and should be avoided. However, at higher rotational speeds (9000-11,000 rpm), the VIP produces a higher pressure head and can pump against a significantly higher afterload (30-40 mm Hg) to support Fontan patients with normal pulmonary resistance.

### Table 2: Mock circulation results for Fontan with various levels of VIP support

<table>
<thead>
<tr>
<th>Case</th>
<th>VIP speed (rpm)</th>
<th>HR (beats/min)</th>
<th>SV (mL)</th>
<th>CO (L/min)</th>
<th>CO % increase</th>
<th>VCP (mm Hg)</th>
<th>PAP (mm Hg)</th>
<th>CAP (mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fontan baseline</td>
<td>—</td>
<td>110</td>
<td>20.0</td>
<td>2.2</td>
<td>—</td>
<td>9</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>0</td>
<td>110</td>
<td>20.1</td>
<td>2.2</td>
<td>—</td>
<td>9</td>
<td>8</td>
<td>2</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>3000</td>
<td>110</td>
<td>20.9</td>
<td>2.3</td>
<td>4.5</td>
<td>9</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>5000</td>
<td>110</td>
<td>21.8</td>
<td>2.4</td>
<td>9.1</td>
<td>9</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>7000</td>
<td>110</td>
<td>24.1</td>
<td>2.65</td>
<td>20.4</td>
<td>8</td>
<td>16</td>
<td>5</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>9000</td>
<td>110</td>
<td>24.5</td>
<td>2.7</td>
<td>22.7</td>
<td>8</td>
<td>25</td>
<td>12</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>11,000</td>
<td>110</td>
<td>24.7</td>
<td>2.72</td>
<td>23.6</td>
<td>8</td>
<td>37</td>
<td>24</td>
</tr>
<tr>
<td>Fontan +VIP</td>
<td>11,000</td>
<td>110</td>
<td>19.1</td>
<td>2.1</td>
<td>—4.5</td>
<td>5</td>
<td>24</td>
<td>21</td>
</tr>
</tbody>
</table>

VC partial clamp

The normal operating range of the pediatric viscous impeller pump is expected to be approximately 5000 to 7000 rpm. At higher operational speeds, the VIP produces a significant pressure head, which may only be needed in pediatric Fontan patients with relative pulmonary hypertension. Importantly, VIP stoppage does not alter the cardiac output or cavopulmonary pressures from baseline values. VIP, Viscous impeller pump; HR, heart rate; SV, stroke volume; CO, cardiac output; CO % increase, percent increase from baseline Fontan cardiac output; VCP, vena caval pressure; PAP, pulmonary artery pressure; CAP, common atrial pressure; VC, vena cava.

**FIGURE 4.** A, Pump hydraulic performance (H-Q). The VIP is capable of providing flows up to 4 L/min and can pump against a pressure head of up to 40 mm Hg. B, Scalar shear stress contours show maximum shear stress of 160 Pa (clinical threshold > 300 Pa), indicating low risk for hemolysis. CFD, Computational fluid dynamic; EXP, hydraulic performance experimental.
precapillary pulmonary hypertension. Physiologic control algorithms to provide optimal cavopulmonary support and ensure patient safety are currently under development.

Negative pressure and vena caval collapse are concerns, especially in pediatric patients who have smaller vessel dimensions and inasmuch as there is no venous reservoir for the pump to draw from in a TCPC. However, negative pressures were not observed, even when the vena cavae were partially clamped (60%) with the VIP operating at the maximum operational speed of 11,000 rpm, indicating low risk for this pump to induce suction collapse of the thin-walled vena cavae. Off-center placement of the VIP at the cavopulmonary junction by up to 80% radius of the pulmonary artery (40% diameter) resulted in negligible reduction in pump flow. Thus, exact placement of the VIP at the cavopulmonary junction, albeit ideal, is not essential. The results of this study also indicate that the VIP is effective in augmenting cavopulmonary flow in the presence of moderate offset between the left and right pulmonary arteries or vena cava anastomoses at the cavopulmonary junction. When VIP rotation is stopped, cavopulmonary flows and pressures return to, but are no less than, baseline (no VIP in the cavopulmonary junction) values, demonstrating that the VIP is not obstructive to Fontan cavopulmonary flow under any circumstance. Numerical simulations confirm this finding and demonstrate that the presence of a nonrotating VIP impeller will optimize cavopulmonary flow by beneficially splitting incoming TCPC flow toward the outlets and minimizing energy loss that otherwise occurs in a TCPC with no device present. Further, no reduction in cavopulmonary flows was observed with nominal values of vena caval offset, indicating that the VIP may be suitable for most Fontan patients.

CFD and hemolysis testing in the mock demonstrated low peak shear stress values and hemolysis rates for the VIP. A plasma free hemoglobin level of 70 mg/dL with the VIP compares favorably with plasma free hemoglobin levels obtained after 6-hour in vitro hemolysis studies with clinically approved blood pumps (plasma free hemoglobin of 80-250 mg/dL). The low hemolysis levels and peak shear stress values indicate that the VIP may be an ideal device for short-term (<30 days) cavopulmonary support.

This study demonstrates that a VIP pump scaled for use in young children is capable of functioning well, from a hydraulic and hemodynamic standpoint, within the more rigorous physiologic environment of smaller vessel size and risk of elevated pulmonary arterial pressures. With VIP support, a patient with single-ventricle Fontan construction, at any stage of life, may be managed with near normal oxygenation, balanced pulmonary/systemic flow ratios, normal cerebral perfusion, normal systemic venous pressure, normal preload, and normal cardiac output. Systemic transition to an unsupported univentricular Fontan circulation is feasible within a 2-week time frame. Support can be weaned after perioperative third spacing and fluid mobilization are complete and lung function is optimal. The systemic venous compartment will have the necessary time for interstitial and oncotic adaptation to the pressure required to independently perfuse the lungs and maintain cardiac output. Thus, VIP cavopulmonary support may enable a direct transition to univentricular Fontan palliation based on more stable 2-ventricle physiology and may limit or eliminate the need for interim staging and enable Fontan conversion in 1 stage.

**Limitations**

Animal models of univentricular Fontan circulation that accurately replicate Fontan hemodynamics do not exist, making it a challenge to test the circulatory response to cavopulmonary assist before clinical application. Computer simulation and mock circulation of the Fontan circulation are representative of clinical observations from a purely hemodynamic viewpoint and are not intended to replace the importance and significance of in vivo models. The biventricular computer simulation and mock circulation model, modified to simulate univentricular Fontan circulation in this study, has been validated and used in the development and testing of several blood pumps. Although incapable of replicating all expected clinical responses, in vitro modeling does provide a controlled environment to test the effects of VIP support and potential failure modes, which is valuable in device development and is not possible in vivo. The ventricular contractility and heart rate were kept constant to reduce experimental variability. Physiologically, heart rate and contractility will increase with increasing preload in accordance with the Frank-Starling mechanism. By extension, it is reasonable to assume that the increase in cardiac output with VIP support may be greater clinically owing to the Frank-Starling response. The mock circulation system has mechanical valves, which may create large aortic valve pressure gradients and ringing during valve closure. The length of tubing in the mock circulation may cause added inertial effects. However, the inertial effects represent less than 2% of the total power and an inerance mismatch would not affect the results significantly. The impeller tested was a rigid rather than expanding prototype and the cavopulmonary junction was idealized from patient data. The risk of infection and thrombosis with the VIP is expected to be similar to that of other catheter-based devices (Intra-aortic balloon pump, Maquet Cardiovascular, Wayne, NJ; and Impella 2.5 and 5.0, ABIOMED Inc, Danvers, Mass) and may limit the period of VIP implantation to 30 days. Although the VIP augments pulmonary and systemic flows, the pulmonary blood flow remains nonpulsatile. Generation of a pulse pressure by modulation of pump operational speed may mitigate any deleterious effects of nonpulsatile pulmonary flows. Despite these limitations,
References